Amerikanische Gesellschaft für Hirudotherapie

Comparative genomics suggests extensive antithrombotic gene expansion in Haemadipsa yanyuanensis

Comparative genomics published in BMC Genomics (2025)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Observational studyGenomik & ProteomikSpeichel-PharmakologieLin Y et al. · BMC genomics, 2025

Abstract

Haemadipsa yanyuanensis Liu & Song, 1977, is a terrestrial blood-feeding leech whose antithrombotic repertoire remains insufficiently characterized. We present its first chromosome-level genome assembly (165.32 Mb across nine chromosomes; BUSCO: 97.6%) using Nanopore long reads, Hi-C scaffolding, and RNA-seq data. We identified 193 putative antithrombotic genes in 15 putative families, representing a 2.2- to 2.7-fold increase in gene number but reduced family diversity compared with aquatic medicinal leeches, including Hirudo nipponia Whitman, 1886, Hirudinaria manillensis Lesson, 1842, and Hirudo medicinalis Linnaeus, 1758. Notably, the putative bdellin, LDTI, and LCI gene families exhibited marked lineage-specific expansions, ranging from 8.7- to 25-fold relative to those of aquatic leeches. In addition, the putative progranulin gene displayed a distinctive structural organization characterized by 122 cysteine residues and nine tandem repeats. Transcriptomic profiling revealed elevated expression of four expanded putative families, suggesting potential roles in terrestrial blood-feeding adaptation. This chromosome-scale genome provides a valuable resource for investigating anticoagulation mechanisms and may inform the development of next-generation antithrombotic therapeutics.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleComparative Study
Indexed MeSH termsAnimalsLeechesGenomicsPhylogenyFibrinolytic AgentsGenomeTranscriptomeGene Expression Profiling

Zusammenfassung

Comparative genomic analysis of the Yanyuan land leech Haemadipsa yanyuanensis showing dramatic expansion of antithrombotic gene families including hirudin-like factors and Kazal-type inhibitors.

Warum dies für die Hirudotherapie relevant ist

This study presents the first chromosome-level genome assembly (165.32 Mb across nine chromosomes; BUSCO 97.6%) of the terrestrial blood-feeding leech Haemadipsa yanyuanensis, identifying 193 putative antithrombotic genes across 15 families—a 2.2- to 2.7-fold increase in gene number but reduced family diversity compared with aquatic medicinal leeches (Hirudo nipponia, Hirudinaria manillensis, Hirudo medicinalis). Bdellin, LDTI, and LCI gene families showed marked lineage-specific expansions (8.7- to 25-fold), with transcriptomic profiling confirming elevated expression of four expanded families, suggesting roles in terrestrial blood-feeding adaptation. This is highly relevant to ASH's domain as it provides a genomic resource for understanding antithrombotic gene diversity and leech salivary repertoire evolution. Caveat: the findings are putative gene identifications based on comparative genomics and transcriptomics with no functional protein validation or bioactivity data presented.

Zitation

Comparative genomics suggests extensive antithrombotic gene expansion in Haemadipsa yanyuanensis.

Lin Y et al. · BMC genomics, 2025

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.